EBV-associated lymphoproliferative disorders: Classification and treatment

Oncologist

Volumn 13, Issue 5, 2008, Pages 577-585

  Carbone, Antonino ^a   Gloghini, Annunziata ^a   Dotti, Giampietro ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

EBV; EBV cell based immunotherapy; EBV associated lymphomas; HIV associated lymphoproliferative disorders; Post transplant associated lymphoproliferative disorders

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTOKINE; DOXORUBICIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD30; PREDNISONE; RITUXIMAB; VINCRISTINE;

B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER RADIOTHERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; EPSTEIN BARR VIRUS; GENE EXPRESSION; GRAFT REJECTION; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOSUPPRESSIVE TREATMENT; LARGE CELL LYMPHOMA; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; NATURAL KILLER T CELL; PATHOGENESIS; PERIPHERAL T CELL LYMPHOMA; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; T CELL LYMPHOMA; VIRUS INFECTION; VIRUS LOAD;

ADULT; DISEASE SUSCEPTIBILITY; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOTHERAPY; LYMPHOMA, B-CELL; LYMPHOMA, T-CELL;

EID: 45749107592     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2008-0036     Document Type: Review

References (75)

1. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004;4:757-768.
2. Elgui de Oliveira D. DNA viruses in human cancer: An integrated overview on fundamental mechanisms of viral carcinogenesis. Cancer Lett 2007;247:182-196.
3. Delecluse HJ, Feederle R, O'Sullivan B et al. Epstein Barr virus-associated tumours: An update for the attention of the working pathologist. J Clin Pathol 2007;60:1358-1364.
4. Du MQ, Bacon CM, Isaacson PG. Kaposi sarcoma-associated herpesvirus/ human herpesvirus 8 and lymphoproliferative disorders. J Clin Pathol 2007;60:1350-1357.
5. Chen YB, Rahemtullah A, Hochberg E. Primary effusion lymphoma. The Oncologist 2007;12:569-576.
6. Thompson MP, Kurzrock R. Epstein-Barr virus and cancer. Clin Cancer Res 2004;10:803-821.
7. Dolcetti R, Guidoboni M, Gloghini A et al. EBV-associated tumors: Pathogenetic insights for improved disease monitoring and treatment. Curr Cancer Ther Rev 2005;1:27-44.
8. Rezk SA, Weiss LM. Epstein-Barr virus-associated lymphoproliferative disorders. Hum Pathol 2007;38:1293-1304.
9. Sbih-Lammali F, Djennaoui D, Belaoui H et al. Transcriptional expression of Epstein-Barr virus genes and proto-oncogenes in north African nasopharyngeal carcinoma. J Med Virol 1996;49:7-14.
10. Liebowitz D, Kieff E. Epstein-Barr virus. In: Roizman B, Whitley RJ, Lopez C, eds. The Human Herpesvirus. Raven Press: New York, 1993:107-172.
11. Cesarman E, Mesri EA. Virus associated lymphomas. Curr Opin Oncol 1999;11:322-332.
12. Niedobitek G, Young LS, Herbst H. Epstein-Barr virus infection and the pathogenesis of malignant lymphomas. Cancer Surv 1997;30:143-162.
13. Hayes DP, Brink AA, Vervoot MB et al. Expression of Epstein-Barr virus (EBV) transcripts encoding homologues to important human proteins in diverse EBV associated diseases. Mol Pathol 1999;52:97-103.
14. Küppers R. B cells under influence: Transformation of B cells by Epstein-Barr virus. Nat Rev Immunol 2003;3:801-812.
15. Wensing B, Farrell PJ. Regulation of cell growth and death by Epstein-Barr virus. Microbes Infect 2000;2:77-84.
16. Okano M. Epstein-Barr virus infection and its role in the expanding spectrum of human diseases. Acta Paediatr 1998;87:11-18.
17. Kelly GL, Milner AE, Baldwin GS et al. Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells. Proc Natl Acad Sci U S A 2006;103:14935-14940.
18. Wilson JB, Bell JL, Levine AJ. Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice. EMBO J 1996;15:3117-3126.
19. Kitagawa N, Goto M, Kurozumi K et al. Epstein-Barr virus-encoded poly(A)(-) RNA supports Burkitt's lymphoma growth through interleukin-10 induction. EMBO J 2000;19:6742-6750.
20. Chapman A, Rickinson A. Epstein-Barr virus in Hodgkin's disease. Ann Oncol 1998;9(suppl 5):S5-S16.
21. Gledhill S, Gallagher A, Jones DB et al. Viral involvement in Hodgkin's disease: Detection of clonal type A Epstein-Barr virus genomes in tumor samples. Br J Cancer 1991;64:227-232.
22. Boyle M, Vasak E, Tschuchnigg M et al. Subtypes of Epstein-Barr virus (EBV) in Hodgkin's disease: Association between B-type EBV and immunocompromise. Blood 1993;81:468-474.
23. Armstrong AA, Alexander FE, Cartwright R et al. Epstein-Barr virus and Hodgkin's disease: Further evidence for the three disease hypothesis. Leukemia 1998;12:1272-1276.
24. Kanzler H, Küppers R, Hansmann ML et al. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med 1996;184:1495-1505.
25. Carbone A, Gloghini A, Gruss HJ et al. CD40 ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin's disease. Am J Pathol 1995;147:912-922.
26. Re D, Küppers R, Diehl V. Molecular pathogenesis of Hodgkin's lymphoma. J Clin Oncol 2005;23:6379-6386.
27. Carbone A, Gloghini A, Gattei V et al. Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines. Blood 1995;85:780-789.
28. Carbone A, Gloghini A, Larocca LM et al. Human immunodeficiency virus-associated Hodgkin's disease derives from post-germinal center B cells. Blood 1999;93:2319-2326.
29. McKhann CF. Primary malignancy in patients undergoing immunosuppression for renal transplantation. Transplantation 1969;8:209-212.
30. Penn I, Hammond W, Brettschneider L et al. Malignant lymphomas in transplantation patients. Transplant Proc 1969;1:106-112.
31. Borish B, Raphael M, Swerdlow SH et al. Lymphoproliferative diseases associated with primary immune disorders. In Jaffe ES, Harris NL, Stein H et al., eds. World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press, 2001:257-259.
32. Chadburn A, Chen JM, Hsu DT et al. The morphologic and molecular genetic categories of posttransplantation lymphoproliferative disorders are clinically relevant. Cancer 1998;82:1978-1987.
33. Cohen JI. Benign and malignant Epstein-Barr virus-associated B-cell lymphoproliferative diseases. Semin Hematol 2003;40:116-123.
34. Hsieh WS, Lemas MV, Ambinder RF. The biology of Epstein- Barr virus in post-transplant lymphoproliferative disease. Transplant Infect Dis 1999;1:204-212.
35. Tanner JE, Alfieri C. The Epstein-Barr virus and post-transplant lymphoproliferative disease: Interplay of immunosuppression, EBV, and the immune system in disease pathogenesis. Transplant Infect Dis 2001;3:60-69.
36. Davis JE, Sherritt MA, Bharadwaj M et al. Determining virological, serological and immunological parameters of EBV infection in the development of PTLD. Int Immunol 2004;16:983-989.
37. Raphael M, Borisch B, Jaffe ES. Lymphomas associated with infection by the human immune deficiency virus (HIV). In: Jaffe ES, Harris NL, Stein H et al., eds. World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press, 2001:260-263.
38. Delecluse HJ, Anagnostopoulos I, Dallenbach F et al. Plasmablastic lymphomas of the oral cavity: A new entity associated with the human immunodeficiency virus infection. Blood 1997;89:1413-1420.
39. Carbone A, Gaidano G, Gloghini A et al. AIDS-related plasmablastic lymphomas of the oral cavity and jaws: A diagnostic dilemma. Ann Otol Rhinol Laryngol 1999;108:95-99.
40. Carbone A, Gloghini A. AIDS-related lymphomas: From pathogenesis to pathology. Br J Haematol 2005;130:662-670.
41. Carbone A, Gloghini A. HHV-8-associated lymphoma: State-of-the-art review. Acta Haematol 2007;117:129-131.
42. Cesarman E, Chang Y, Moore PS et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 1995;332:1186-1191.
43. Carbone A, Gloghini A, Vaccher E et al. Kaposi's sarcoma-associated herpesvirus DNA sequences in AIDS-related and AIDS-unrelated lymphomatous effusions. Br J Haematol 1996;94:533-543.
44. Nador RG, Cesarman E, Chadburn A et al. Primary effusion lymphoma: A distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood 1996;88:645-656.
45. Gaidano G, Capello D, Cilia AM et al. Genetic characterization of HHV-8/KSHV-positive primary effusion lymphoma reveals frequent mutations of BCL6: Implications for disease pathogenesis and histogenesis. Genes Chromosomes Cancer 1999;24:16-23.
46. Fan W, Bubman D, Chadburn A et al. Distinct subsets of primary effusion lymphoma can be identified based on their cellular gene expression profile and viral association. J Virol 2005;79:1244-1251.
47. Jaffe ES, Ralfkiaer E. Mature T-cell and NK-cell neoplasms. In: Jaffe ES, Harris NL, Stein H et al., eds. World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissue. Lyon, France: IARC Press, 2001:189-235.
48. Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994;84:1361-1392.
49. Went P, Agostinelli C, Gallamini A et al. Marker expression in peripheral T-cell lymphoma: A proposed clinical-pathologic prognostic score. J Clin Oncol 2006;24:2472-2479.
50. Ballester B, Ramuz O, Gisselbrecht C et al. Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas. Oncogene 2006;25:1560-1570.
51. Dupuis J, Boye K, Martin N et al. Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): A new diagnostic marker providing evidence that AITL derives from follicular helper T cells. Am J Surg Pathol 2006;30:490-494.
52. de Leval L, Rickman DS, Thielen C et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood 2007;109:4952-4963.
53. Baumforth KR, Young LS, Flavell KJ et al. The Epstein-Barr virus and its association with human cancers. Mol Pathol 1999;52:307-322.
54. International Agency for Research on Cancer. Epstein-Barr virus and Kaposi's sarcoma herpesvirus/human herpesvirus 8. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Volume 70. Lyon, France: IARC Press, 1997:45-52.
55. Paya CV, Fung JJ, Nalesnik MA et al. Epstein-Barr virus-induced post-transplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 1999;68:1517-1525.
56. Lee TC, Savoldo B, Rooney CM et al. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant 2005;5:2222-2228.
57. Kuehnle I, Huls MH, Liu Z et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 2000;95:1502-1505.
58. Milpied N, Vasseur B, Parquet N et al. Humanized anti-CD20 monoclonal antibody (rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients. Ann Oncol 2000;11(suppl 1):113-116.
59. Dotti G, Rambaldi A, Fiocchi R et al. Anti-CD20 antibody (rituximab) administration in patients with late occurring lymphomas after solid organ transplant. Haematologica 2001;86:618-623.
60. Choquet S, Leblond V, Herbrecht R et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: Results of a prospective multicenter phase 2 study. Blood 2006;107:3053-3057.
61. Savoldo B, Rooney CM, Quiros-Tejeira RE et al. Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. Am J Transplant 2005;5:566-572.
62. Dotti G, Fiocchi R, Motta T et al. Lymphomas occurring late after solidorgan transplantation: Influence of treatment on the clinical outcome. Transplantation 2002;74:1095-1102.
63. Gross TG, Bucuvalas JC, Park JR et al. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. J Clin Oncol 2005;23:6481-6488.
64. Choquet S, Trappe R, Leblond V et al. CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation. Haematologica 2007;92:273-274.
65. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. Nephrol Dial Transplant 2002;17(suppl 4):1-67.
66. Rooney CM, Smith CA, Ng CY et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998;92:1549-1555.
67. Khanna R, Bell S, Sherritt M et al. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci U S A 1999;96:10391-10396.
68. Comoli P, Labirio M, Basso S et al. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood 2002;99:2592-2598.
69. Savoldo B, Goss JA, Hammer MM et al. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood 2006;108:2942-2949.
70. Haque T, Wilkie GM, Taylor C et al. Treatment of Epstein-Barr-virus- positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 2002;360:436-442.
71. Yung L, Linch D. Hodgkin's lymphoma. Lancet 2003;361:943-951.
72. Ansell SM, Horwitz SM, Engert A et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 2007;25:2764-2769.
73. Roskrow MA, Suzuki N, Gan Y et al. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood 1998;91:2925-2934.
74. Straathof KC, Bollard CM, Rooney CM et al. Immunotherapy for Epstein-Barr virus-associated cancers in children. The Oncologist 2003;8:83-98.
75. Dotti G, Savoldo B, Pule M et al. Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis. Blood 2005;105:4677-4684.